Voluntary nationwide recall: Clonazepam (Endo – July)
Sep. 2024Pharmacy Updates
Endo USA Inc. has recalled one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. Clonazepam is used to treat panic disorder and certain seizures.
This product is being recalled because the cartons of some packs show the product strength as 0.125 mg, not 0.25 mg, due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25 mg.
Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.
As of July 16, there had been no reports of adverse events related to this recall.
To learn more about this recall:
- Call Inmar Inc. at 1-877-890-0765. Help is available Monday through Friday from 9 a.m. to 5 p.m. ET.
- Visit the FDA website.
Recent Announcements
Special notice: Important policy changes
Effective June 1, 2025, UPMC Health Plan will be implementing policy changes that will require providers to obtain prior authorizations for services listed in the following policies. For more information, please visit upmchp.us/policiesandprocedures.May 2025Important Notices
Provider OnLine Enhancements
Provider OnLine will be launching enhancements to the authorization process on April 18, 2025. The enhancement will include the following updates:Apr. 2025Important Notices
Fostering Trust in Vaccinations Through Shared Decision Making
Please join us for a live, CME-accredited webinar on Wednesday, June 4, from noon to 1 p.m. that will provide an overview of fostering trust in vaccinations through shared decision making.Apr. 2025Education/Webinars